These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 19807677)
1. Recent patents in antiviral siRNAs. Saravolac EG; Wong JP; Cairns MJ Recent Pat Antiinfect Drug Discov; 2010 Jan; 5(1):44-57. PubMed ID: 19807677 [TBL] [Abstract][Full Text] [Related]
2. Innovations in siRNA research: a technology comes of age. Hefferon KL Recent Pat Antiinfect Drug Discov; 2010 Nov; 5(3):226-39. PubMed ID: 20812899 [TBL] [Abstract][Full Text] [Related]
5. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials. DeVincenzo JP Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462 [TBL] [Abstract][Full Text] [Related]
6. A review on current status of antiviral siRNA. Qureshi A; Tantray VG; Kirmani AR; Ahangar AG Rev Med Virol; 2018 Jul; 28(4):e1976. PubMed ID: 29656441 [TBL] [Abstract][Full Text] [Related]
7. Journey of siRNA: Clinical Developments and Targeted Delivery. Nikam RR; Gore KR Nucleic Acid Ther; 2018 Aug; 28(4):209-224. PubMed ID: 29584585 [TBL] [Abstract][Full Text] [Related]
9. [RNAi-mediated specific gene silencing and its application to medical treatments of viral infectious disease]. Minoshima H; Suyama E; Kawasaki H; Taira K Uirusu; 2003 Jun; 53(1):7-14. PubMed ID: 14556497 [No Abstract] [Full Text] [Related]
10. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Huang C; Li M; Chen C; Yao Q Expert Opin Ther Targets; 2008 May; 12(5):637-45. PubMed ID: 18410245 [TBL] [Abstract][Full Text] [Related]
11. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968 [TBL] [Abstract][Full Text] [Related]
12. Molecular therapeutics of cancer by means of electroporation-based transfer of siRNAs and EBV-based expression vectors. Mazda O; Kishida T Front Biosci (Elite Ed); 2009 Jun; 1(1):316-31. PubMed ID: 19482649 [TBL] [Abstract][Full Text] [Related]
13. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs. Wagner A; Bock CT; Fechner H; Kurreck J Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598 [No Abstract] [Full Text] [Related]
15. Therapeutic face of RNAi: in vivo challenges. Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911 [TBL] [Abstract][Full Text] [Related]
17. [SiRNA technology, the gene therapy of the future?]. Rácz Z; Hamar P Orv Hetil; 2008 Jan; 149(4):153-9. PubMed ID: 18201957 [TBL] [Abstract][Full Text] [Related]
18. Delivering siRNA with Dendrimers: In Vivo Applications. Leiro V; Santos SD; Pego AP Curr Gene Ther; 2017; 17(2):105-119. PubMed ID: 28494741 [TBL] [Abstract][Full Text] [Related]
19. The cutting-edge technologies of siRNA delivery and their application in clinical trials. Lee K; Jang B; Lee YR; Suh EY; Yoo JS; Lee MJ; Lee JY; Lee H Arch Pharm Res; 2018 Sep; 41(9):867-874. PubMed ID: 30136248 [TBL] [Abstract][Full Text] [Related]
20. Gene silencing of HIV-1 by RNA interference. Takaku H Antivir Chem Chemother; 2004 Mar; 15(2):57-65. PubMed ID: 15185724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]